Guardian Health to Develop BloodBased Diagnostic Tests for AstraZeneca\'s Tagrisso

Guardian Health to Develop Blood-Based Diagnostic Tests for AstraZeneca's Tagrisso

15:00 EST 17 Dec 2018 | Pharmaceutical Processing

News
Under the agreement, Guardant Health will develop and pursue FDA approval for a companion diagnostic test for Tagrisso, AstraZeneca’s EGFR inhibitor.
Contributed Author: 
Guardant Health
Topics: 
Oncology

More From BioPortfolio on "Guardian Health to Develop Blood-Based Diagnostic Tests for AstraZeneca's Tagrisso"